Bio News
Japan-based Takeda has received US Food and Drug Administration (FDA) approval for Mymiro (rusfertide) to treat erythrocytosis in adults with polycythemia vera. Mymiro is the first therapy in the hepcidin mimetic class, which regulates iron distribution in the body and excessive red blood cell production. Takeda is working with regulatory agencies outside the United States to pursue plans to make Mymiro available to patients worldwide.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
